265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00130286 (ClinicalTrials.gov) | March 2005 | 12/8/2005 | Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance | Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance | HIV-Associated Lipodystrophy Syndrome;Insulin Resistance;HIV Infections;Metabolic Syndrome X;Body Weight Changes | Drug: Rosiglitazone;Drug: Recombinant human growth hormone + rosiglitazone | Weill Medical College of Cornell University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | 65 Years | All | 77 | Phase 1/Phase 2 | United States |